Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: A European perspective

Massimo Colombo, Jean Luc Raoul, Riccardo Lencioni, Peter R. Galle, Jessica Zucman-Rossi, Rafael Bañares, Daniel Seehofer, Peter Neuhaus, Philip Johnson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.

Original languageEnglish (US)
Pages (from-to)639-651
Number of pages13
JournalEuropean Journal of Gastroenterology and Hepatology
Volume25
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Clinical Trials
Therapeutics
Chronic Hepatitis B
Liver Failure
Virus Diseases
Hepatitis B virus
Alcohol Drinking
Hepacivirus
Early Diagnosis
Fibrosis
Obesity
Biomarkers
Guidelines
Recurrence
Mortality
Liver
Incidence
Population
Neoplasms

Keywords

  • brivanib
  • everolimus
  • hepatocellular carcinoma
  • linifanib
  • radiofrequency ablation
  • ramucirumab
  • sorafenib
  • transarterial chemoembolization
  • transplantation

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma : A European perspective. / Colombo, Massimo; Raoul, Jean Luc; Lencioni, Riccardo; Galle, Peter R.; Zucman-Rossi, Jessica; Bañares, Rafael; Seehofer, Daniel; Neuhaus, Peter; Johnson, Philip.

In: European Journal of Gastroenterology and Hepatology, Vol. 25, No. 6, 06.2013, p. 639-651.

Research output: Contribution to journalArticle

Colombo, M, Raoul, JL, Lencioni, R, Galle, PR, Zucman-Rossi, J, Bañares, R, Seehofer, D, Neuhaus, P & Johnson, P 2013, 'Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: A European perspective', European Journal of Gastroenterology and Hepatology, vol. 25, no. 6, pp. 639-651. https://doi.org/10.1097/MEG.0b013e32835e33bb
Colombo, Massimo ; Raoul, Jean Luc ; Lencioni, Riccardo ; Galle, Peter R. ; Zucman-Rossi, Jessica ; Bañares, Rafael ; Seehofer, Daniel ; Neuhaus, Peter ; Johnson, Philip. / Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma : A European perspective. In: European Journal of Gastroenterology and Hepatology. 2013 ; Vol. 25, No. 6. pp. 639-651.
@article{53872c811add475eaaa2e13ff3bd199e,
title = "Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: A European perspective",
abstract = "Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.",
keywords = "brivanib, everolimus, hepatocellular carcinoma, linifanib, radiofrequency ablation, ramucirumab, sorafenib, transarterial chemoembolization, transplantation",
author = "Massimo Colombo and Raoul, {Jean Luc} and Riccardo Lencioni and Galle, {Peter R.} and Jessica Zucman-Rossi and Rafael Ba{\~n}ares and Daniel Seehofer and Peter Neuhaus and Philip Johnson",
year = "2013",
month = "6",
doi = "10.1097/MEG.0b013e32835e33bb",
language = "English (US)",
volume = "25",
pages = "639--651",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma

T2 - A European perspective

AU - Colombo, Massimo

AU - Raoul, Jean Luc

AU - Lencioni, Riccardo

AU - Galle, Peter R.

AU - Zucman-Rossi, Jessica

AU - Bañares, Rafael

AU - Seehofer, Daniel

AU - Neuhaus, Peter

AU - Johnson, Philip

PY - 2013/6

Y1 - 2013/6

N2 - Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.

AB - Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.

KW - brivanib

KW - everolimus

KW - hepatocellular carcinoma

KW - linifanib

KW - radiofrequency ablation

KW - ramucirumab

KW - sorafenib

KW - transarterial chemoembolization

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84877121118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877121118&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e32835e33bb

DO - 10.1097/MEG.0b013e32835e33bb

M3 - Article

C2 - 23628963

AN - SCOPUS:84877121118

VL - 25

SP - 639

EP - 651

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 6

ER -